VEGFA and glioblastoma: Certain targeted therapies for RTK pathways have significant efficacy for many solid tumors such as breast cancer and lung cancer, but targeted therapies for epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) in glioblastoma often result in resistance due to activation of the MET signaling pathway [13–16].